--- title: 'Regulatory Daily Summary: What Happened on October 6, 2026' headline: UK adopts 44 health-AI recommendations and opens new testing phase description: The DOJ narrowed corporate fraud priorities, putting health care, drug diversion and FDA violations in focus. url: https://thebench.bio/news/regulatory/2026-10-06 topic: regulatory date: '2026-10-06' covers: - '2026-10-06' date_published: '2026-10-06T12:03:45Z' date_modified: '2026-10-06T18:50:29Z' sources: 3 publisher: The Bench (thebench.bio) --- # Regulatory Daily Summary: What Happened on October 6, 2026 **UK adopts 44 health-AI recommendations and opens new testing phase** The DOJ narrowed corporate fraud priorities, putting health care, drug diversion and FDA violations in focus. ## Today in brief The UK accepted all 44 recommendations on health-care AI regulation and opened a new round of testing for oversight of AI medical devices after they reach the market. [1] A DOJ directive named four areas for priority corporate investigations, including health care fraud, drug diversion and violations of FDA law. [2] ## UK accepts all 44 health-AI recommendations The UK government accepted all 44 recommendations from its National Commission into the Regulation of AI in Healthcare and outlined plans to deliver them across the country. [1] The Medicines and Healthcare products Regulatory Agency opened applications for the third phase of its AI Airlock program, which will test post-market monitoring and lifecycle oversight for AI-enabled medical devices. [1] The agency said it plans to issue draft guidance on managing changes to these devices by December 2026 and consult in 2027 on how to qualify and classify them. [1] The government committed to exploring staged authorization that could allow some AI tools into National Health Service use earlier under supervision while further real-world evidence is gathered. [1] A full implementation roadmap, with timelines and responsibilities, is due by spring 2027, and the AI Airlock program has secured three more years of government funding. [1] The first participants in the third phase are expected to be selected in November 2026. [1] ## DOJ names health care and FDA conduct among corporate fraud priorities On October 1, Assistant Attorney General Colin M. McDonald issued a directive identifying four areas for priority corporate investigations, including health care fraud, drug diversion and violations of the Federal Food, Drug, and Cosmetic Act. [2] The directive narrows the department's corporate enforcement focus after its April 2026 launch of a department-wide Corporate Enforcement and Voluntary Self-Disclosure Policy. [2] Legal commentators Andrew J. Hull and Anne K. Walsh said the directive tells prosecutors how to apply that policy, rather than changing it. [2] ## Also worth knowing - Optogenetics received Nobel Prize recognition as its first therapy neared an FDA decision. [3] ## The day in numbers - **44**: Health-AI recommendations accepted by the UK government. [1] - **4**: Priority areas for corporate investigations named in the DOJ directive. [2] - **3 years**: Additional government funding secured for the UK's AI Airlock program. [1] ## Also published - [UK backs all health AI proposals in commission report](), pharmaphorum - [New York declares measles outbreak a "disaster emergency"](), pharmaphorum - [Opinion: Why the FDA should not approve an ineffective multicancer screening test](), STAT Biotech - [In Rare Trials Summit keynote, BIO expert highlights lives touched by PPRV](), Bio.News - [Operation TrialBlazer Leveraging New and Anticipated US Policy Changes in Early Development](), Applied Clinical Trials ## Sources 1. [Government backs recommendations of NHS doctors-led AI Commission](), MHRA, 2026-10-06 2. [Last One Standing: DOJ Narrows Fraud Enforcement Priorities to Companies that Violate the CSA and FDC Act](), FDA Law Blog, 2026-10-06 3. [Nobel Prize for optogenetics arrives as first therapy nears FDA decision](), BioCentury, 2026-10-06 --- The Bench wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: